Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jilin Province Huinan Changlong Bio-pharmacy Co EBITDA Margin % Related Terms
Jilin Province Huinan Changlong Bio-pharmacy Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co EBITDA Margin % Chart
Jilin Province Huinan Changlong Bio-pharmacy Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Jilin Province Huinan Changlong Bio-pharmacy Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jilin Province Huinan Changlong Bio-pharmacy Co EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) has a EBITDA Margin % of 30.68% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. This is near median its historical median of 28.92. Over the past decade, Jilin Province Huinan Changlong Bio-pharmacy Co's EBITDA Margin % has ranged from 26.82 to 32.62. According to the industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #141 out of 953 companies in the Drug Manufacturers industry, placing it in the top 14.8%.
Is Jilin Province Huinan Changlong Bio-pharmacy Co's EBITDA Margin % too high?
Jilin Province Huinan Changlong Bio-pharmacy Co's current EBITDA Margin % of 30.68% is near median its 10-year median of 28.92. Over the past 10 years, this metric has ranged from a low of 26.82 to a high of 32.62. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 30.68% is 145.6% above this industry median. Based on the distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #141 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jilin Province Huinan Changlong Bio-pharmacy Co has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Jilin Province Huinan Changlong Bio-pharmacy Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #141 out of 953 companies for EBITDA Margin %. This places Jilin Province Huinan Changlong Bio-pharmacy Co in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 30.68% is 145.6% above this benchmark. Historically, Jilin Province Huinan Changlong Bio-pharmacy Co's own EBITDA Margin % has ranged from 26.82 to 32.62 over the past decade. While the company's 10-year median is 28.92 vs. the industry median of 12.49, Jilin Province Huinan Changlong Bio-pharmacy Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jilin Province Huinan Changlong Bio-pharmacy Co's current EBITDA Margin % of 30.68% is 145.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jilin Province Huinan Changlong Bio-pharmacy Co's current EBITDA Margin % is 30.68%, which is near median its own 10-year median of 28.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jilin Province Huinan Changlong Bio-pharmacy Co stock overvalued right now?
Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) has a current EBITDA Margin % of 30.68%. The stock's GF Value™ is €0.18, compared to a current price of €0.25 — trading 37.8% above its estimated fair value. The current EBITDA Margin % is 30.68%, which is near median its 10-year median of 28.92 and 145.6% above the Drug Manufacturers industry median of 12.49. Jilin Province Huinan Changlong Bio-pharmacy Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL), the current EBITDA Margin % is 30.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jilin Province Huinan Changlong Bio-pharmacy Co (FRA:JIL) Overvalued in 2026?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co stock appears to be overvalued.
The current stock price of €0.25 is trading 37.8% above its estimated GF Value™ of €0.18.
Key valuation signals for FRA:JIL:
EBITDA Margin %: 30.68% (near median its 10-year median of 28.92)
GF Value™: €0.18 vs. price of €0.25 (37.8% above fair value)
Industry Position: 145.6% above the Drug Manufacturers median (#141 of 953)
No single metric tells the full story. See the FRA:JIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jilin Province Huinan Changlong Bio-pharmacy Co Business Description
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
81GF Score
Get the complete analysis for FRA:JIL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JIL has been successfully added to your 
